Risk of nephrogenic systemic fibrosis (NSF)

In this large cohort of 94,917 patients who received gadolinium-based contrast over an 8 year period, the risk of developing NSF was 1% among hemodialysis patients and 0.8% among renal transplant patients (abstract). Although retrospective, the large cohort study helps to quantify the risk of NSF among patients with significant renal insufficiency.

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment